Abstract
Introduction:
Peritoneal carcinomatosis is a rare finding in metastatic prostate cancer. In the literature peritoneal carcinomatosis is usually reported in its final stages with multiple metastases. A single peritoneal carcinomatosis with no further metastases is a very rare finding.
Case report:
We report the case of a 75-year-old patient with initial ischuria. A prostate cancer could be confirmed and the further diagnostics showed no metastasis. In a transperitoneal approach for laparoscopic pelvic lymphadenectomy a peritoneal carcinomatosis from prostate cancer was proven. A complete antiandrogen therapy was started and PSA decreased for more than 14 months to a stable level of < 1 microg/L.
Conclusion:
An isolated peritoneal carcinomatosis from prostate cancer is a very rare finding. The complete antiandrogen therapy is effective.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adenocarcinoma* / diagnosis
-
Adenocarcinoma* / drug therapy
-
Adenocarcinoma* / secondary
-
Adenocarcinoma* / surgery
-
Aged
-
Androgen Antagonists / therapeutic use
-
Anilides / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Follow-Up Studies
-
Goserelin / therapeutic use
-
Humans
-
Lymph Node Excision
-
Male
-
Nitriles / therapeutic use
-
Peritoneal Neoplasms / diagnosis
-
Peritoneal Neoplasms / drug therapy
-
Peritoneal Neoplasms / pathology
-
Peritoneal Neoplasms / secondary*
-
Peritoneum / pathology
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms* / diagnosis
-
Prostatic Neoplasms* / drug therapy
-
Prostatic Neoplasms* / surgery
-
Time Factors
-
Tosyl Compounds / therapeutic use
-
Transurethral Resection of Prostate
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Anilides
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Nitriles
-
Tosyl Compounds
-
Goserelin
-
bicalutamide
-
Prostate-Specific Antigen